In a recent newsletter, the US FDA highlighted the important role Morphologically-Directed Raman Spectroscopy (MRDS) can play in supporting the development of generic drug products. The component-specific particle size and shape distribution data generated by this technique can aid sponsors with pinpointing the formulation characteristics and possible manufacturing route used for a Reference Listed Drug (RLD) product, and provides the in vitro data required to support bioequivalence studies. This webinar will consider the workflow associated with RLD deformulation and will introduce the technique of MDRS and its application in developing complex generics including Oral Solid Dose (OSD), Topical and OINDP formulations.